Encephalopathy. Both models display severe seizures and early mortality. We found no prolongation of survival between Scn1b
Introduction
Deletion of Mapt, encoding the microtubule-binding protein Tau, has been shown to attenuate hyperexcitability and prevent disease in a mouse model of Alzheimer's Disease with epilepsy, 1 the Kcna1 À/À mouse model of temporal lobe epilepsy, 2 the Scn1a R1407X mouse model of Dravet syndrome (DS), 3 and bang-sensitive Drosophila mutants. 2 As a result of this work, Tau has been proposed to be a viable target for the development of novel anti-epileptic therapeutic agents. To investigate whether the effect of Tau depletion is generalizable across additional gene models of epilepsy with premature lethality, we conducted a similar experiment using two different models of sodium channel gene-linked epileptic encephalopathy: the Scn1b À/À mouse model of DS 4 and the Scn8a N1768D/+ model of Early Infantile Epileptic Encephalopathy (EIEE13). This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Scn1b encodes the b1 and b1B subunits of voltagegated sodium channels. 6 Homozygous Scn1b À/À mice are underweight, have cardiac defects, develop severe seizures at approximately postnatal day (P) 10, and 100% die by approximately P21. SCN1B is the only known genetic link to DS that is due to recessive inheritance. 7, 8 The limited number of reported SCN1B-linked DS cases show seizure onset in the first months of life, dramatic cognitive and motor delays, microcephaly, generalized wasting, severe kyphoscoliosis, central hypotonia, and spastic quadriplegia. 7, 8 SCN8A encodes Na v 1.6, a poreforming a subunit of the voltage-gated sodium channel. Heterozygous missense mutations of SCN8A have been identified in more than 150 individuals with SCN8A-EIEE13 many of which exhibit gain-of-function features. 9 A mouse model expressing the patient mutation p.Asn1758Asp (N1768D) exhibits seizure onset at 2-5 months of age. 5, 10 Death is usually observed within 1 week of seizure onset. 11 Since SCN1B-linked DS and SCN8A-linked EIEE13 are both resistant to multiple anti-epileptic drugs, there is a major need for the development of novel therapeutics for these devastating epilepsy syndromes. to N9 of the backcross to strain C57BL/6J. Male and female mice were used for all experiments. Mouse survival was monitored twice daily by individuals blinded to genotype. For the Scn1b mice, half of the animals were bred and analyzed at the University of Michigan and half at Baylor
Methods
College of Medicine. There were no differences in the results and thus the data were pooled. PCR analysis of mouse tail DNA: DNA was prepared from mouse tail biopsies at P 10-14 using standard methods. 
Statistical analysis
Mouse survival was analyzed by Kaplan-Meier Log Rank (Mantel-Cox).
Results
In contrast to Kcna1 À/À and Scn1a R1407X mice, Mapt deletion had no observable effects on survival of Scn1b DS mice. Scn1b Although affected mice were too young and too small for electroencephalographic monitoring prior to their death in the third postnatal week, all three groups of animals showed similar and clearly visible behavioral seizures up until death. In addition, the time of death was not significantly different between genotypes. Deletion of Mapt alleles also had no effect on the survival of Scn8a N1768D/+ mice. (Fig. 2) .
Discussion
We report that the effects of Mapt deletion on genetic models of neural hyperexcitability are not uniform across all mouse models of epileptic ion channelopathy. Mice bearing the null mutation in Scn1b, a regulatory subunit of voltage-gated neuronal and cardiac sodium channels, show epilepsy even in the absence of Tau protein, and loss of Tau does not prevent or delay premature lethality in this model. This is likely explained by the increased molecular complexity of Scn1b interactions with ion channel pore-forming subunits. The mouse phenotype of SCN1B-linked DS 4,8 is more severe than models of SCN1A-linked DS, 14, 15 and may involve more subclasses of neurons and brain regions. b1/b1B subunits associate with and modulate the voltage-gating properties of all sodium channel and some potassium channel a subunits. 6 b1 and b1B are multifunctional, with nonconducting functions resembling those of immunoglobulin superfamily cell adhesion molecules. 6 In addition to brain, Scn1b is expressed in heart, where it contributes to the regulation of cardiomyocyte excitability and excitation-contraction coupling. 16, 17 SCN1B mutations are linked to cardiac arrhythmia in humans and Scn1b À/À mice have prolonged QT and RR intervals on the ECG. 18 Scn1b is also expressed in pancreatic beta cells. metabolic hypoglycemic phenotype due to abnormal insulin and glucagon release, likely contributing to failure to thrive and early neurologic hypofunction. 19 Thus, SCN1B-linked mortality may relate to combined downstream excitability disturbances in brain, heart, and neuroendocrine cells, not all of which can be rescued by loss of Tau, and the human disease may be more challenging in terms of therapeutic development.
SCN8A gain-of-function mutations are associated with EIEE13, with onset ranging from prenatal life to 1 year of age. The functional effects of patient mutations in this pore-forming subunit include premature channel opening and delayed channel inactivation. 9 Elevated neuronal firing rates have been observed in hippocampal 20 and cortical 21 neurons from mice carrying the patient mutation SCN8A-N1768D, which is located in the last transmembrane segment of the channel. Na v 1.6 is concentrated at the axon initial segment (AIS), where it mediates action potential initiation in neurons throughout the CNS and PNS. The lack of effect of Mapt deletion on survival of mice with the N1768D mutation suggests that Tau may not be involved in the mechanism of Na v 1.6 localization to the AIS. SCN8A is also expressed at low abundance in cardiac myocytes, which exhibit arrhythmic contractions and altered calcium handling in Scn8a N1768D/+ mice. 22 The role of cardiac arrhythmia in premature lethality of this mouse model remains unclear. At the cellular level, the effects of gain-of-function mutations of SCN8A are quite distinct from the loss-of-function mutations of SCN1A responsible for DS. How this difference in mechanism leads to divergent responses to Mapt deletion is a question for the future. The mechanism of sudden unexpected death in epilepsy (SUDEP) in epileptic encephalopathy is not known, although spreading depolarization to the brainstem, respiratory compromise, autonomic dysfunction, and cardiac arrhythmias have been implicated. [22] [23] [24] [25] [26] [27] Mapt deletion, which has been shown to prolong life in the Kv1.1 null model of SUDEP, also restores the normal brainstem threshold for spreading depression, 23 possibly implicating Mapt in SUDEP mechanisms. Nevertheless, our results provide the first indication that targeting Tau will not provide general protection against premature lethality among all genetic channelopathies, which may require development of gene-specific therapies for individual subtypes of epileptic encephalopathy. 
